The FDA Approves a Landmark Cancer Drug
CAR T-cell therapy turns the body’s own immune systems against cancer with genetic engineering.
by Sarah Zhang
Aug 30, 2017
3 minutes
The Food and Drug Administration on Wednesday approved a new therapy to treat leukemia in kids and young adults—a decision whose importance is as much symbolic as it is practical.
Kymriah, from the Swiss pharmaceutical company Novartis, is a cancer therapy that represents several things at once: a game-changing way to treat cancer through genetic engineering, a novel paradigm for the biotech business, and the latest turn in the debate over just how astronomically expensive a life-saving therapy can be.
Kymriah is strikingly
You’re reading a preview, subscribe to read more.
Start your free 30 days